Skip to main content

PIK3CA Biological Pathways Reviews

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Andrew Renehan, MD, PhD
Videos
04/16/2026
Andrew Renehan, MD, PhD
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD, discusses findings from the PrefCoRe study evaluating patient preferences for watch-and-wait versus surgery after clinical complete response in locally advanced rectal cancer.
Andrew Renehan, MD, PhD,...
04/16/2026
Oncology
Michael Pishvaian, MD, PhD
Videos
04/15/2026
Michael Pishvaian, MD, PhD
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD, discusses the phase 3 TIGeR-PaC study evaluating intra-arterial gemcitabine among patients with locally advanced pancreatic cancer.
Michael Pishvaian, MD, PhD,...
04/15/2026
Oncology
Angela Hirbe, MD, PhD
Videos
04/14/2026
Angela Hirbe, MD, PhD
Angela Hirbe, MD, PhD, discusses long-term follow-up results from the phase 2b ReNeu trial evaluating mirdametinib among adult and pediatric patients with inoperable, symptomatic NF1-associated plexiform neurofibromas.
Angela Hirbe, MD, PhD, discusses long-term follow-up results from the phase 2b ReNeu trial evaluating mirdametinib among adult and pediatric patients with inoperable, symptomatic NF1-associated plexiform neurofibromas.
Angela Hirbe, MD, PhD, discusses...
04/14/2026
Oncology
Binod Dhakal, MD
Videos
04/13/2026
Binod Dhakal, MD
Binod Dhakal, MD, discusses results from the CARTITUDE-4 trial evaluating the impact of bridging therapy response in relapsed multiple myeloma refractory to lenalidomide.
Binod Dhakal, MD, discusses results from the CARTITUDE-4 trial evaluating the impact of bridging therapy response in relapsed multiple myeloma refractory to lenalidomide.
Binod Dhakal, MD, discusses...
04/13/2026
Oncology
Jennifer Brown, MD, PhD
Videos
04/13/2026
Jennifer Brown, MD, PhD
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD, discusses mechanisms of resistance to BTKi in chronic lymphocytic leukemia, including mutations associated with both covalent and non-covalent agents.
Jennifer Brown, MD, PhD,...
04/13/2026
Oncology
Luciano Costa, MD
Videos
04/13/2026
Luciano J. Costa
Luciano Costa, MD, discusses long-term results from the CARTITUDE-4 trial evaluating ciltacabtagene autoleucel in patients with of standard-risk relapsed/refractory multiple myeloma.
Luciano Costa, MD, discusses long-term results from the CARTITUDE-4 trial evaluating ciltacabtagene autoleucel in patients with of standard-risk relapsed/refractory multiple myeloma.
Luciano Costa, MD, discusses...
04/13/2026
Oncology
Victor Jimenez Zepeda, MD
Videos
04/10/2026
Victor H. Jimenez Zepeda, MD
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD, discusses the evolving management of patients with high-risk smoldering multiple myeloma.
Victor Jimenez Zepeda, MD,...
04/10/2026
Oncology
Erin Mulvey, MD
Videos
04/10/2026
Erin Mulvey, MD
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter Symposium, Erin Mulvey, MD, discusses the evolving treatment landscape for Richter transformation.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Catherine Diefenbach, MD
Videos
04/10/2026
Catherine Diefenbach, MD
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.
At the 2026 LL&M Winter Symposium in Amelia Island, Florida, Catherine Diefenbach, MD, discusses key updates in Hodgkin lymphoma, as presented at ASH 2025.
At the 2026 LL&M Winter...
04/10/2026
Oncology
Raajit K. Rampal, MD, PhD
Videos
04/09/2026
Raajit Rampal, MD, PhD
Raajit K. Rampal, MD, PhD, explains his frontline treatment choices for the case of a patient with low-risk polycythemia vera.
Raajit K. Rampal, MD, PhD, explains his frontline treatment choices for the case of a patient with low-risk polycythemia vera.
Raajit K. Rampal, MD, PhD,...
04/09/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
News
04/17/2026
Emily Estrada
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial demonstrate that camizestrant plus capivasertib shows strong clinical promise in endocrine-resistant patients with ER-positive, HER2-negative advanced breast cancer.
Results from the SERENA-1 trial...
04/17/2026
Oncology
News
04/17/2026
Emily Estrada
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with late-relapsing DLBCL, R-CHOP-like therapy retreatment produced meaningful response rates and survival outcomes, though many patients required less intensive therapies at relapse and outcomes remained influenced by...
In older patients with...
04/17/2026
Oncology
News
04/15/2026
Emily Estrada
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase 1b/2 trial demonstrate that the addition of the PP2A inhibitor LB-100 to dostarlimab shows encouraging clinical efficacy with manageable safety among patients with platinum-resistant ovarian clear cell...
Results from an ongoing, phase...
04/15/2026
Oncology
News
04/15/2026
Emily Estrada
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective cohort study demonstrate that longitudinal ctDNA monitoring can potentially serve as a strong, real-time biomarker for response and recurrence in advanced, high-grade serous ovarian cancer.
Results from a prospective...
04/15/2026
Oncology
News
04/14/2026
Stephanie Holland
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3 NRG-GY019 trial confirm that letrozole alone is inferior to chemotherapy followed by letrozole among patients with low-grade serous carcinomas.
Results from the phase 3...
04/14/2026
Oncology
News
04/13/2026
Stephanie Holland
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results from the phase 3 ROSELLA trial demonstrate that the addition of relacorilant to nab-paclitaxel significantly improved survival compared with nab-paclitaxel alone in platinum-resistant ovarian cancer.
Final overall survival results...
04/13/2026
Oncology
News
04/10/2026
Stephanie Holland
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS trial demonstrate that carfilzomib plus lenalidomide and dexamethasone significantly improves PFS in newly diagnosed patients with multiple myeloma following autologous hematopoietic stem-cell transplantation.
Results from the phase 3 ATLAS...
04/10/2026
Oncology
News
04/10/2026
Stephanie Holland
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW study demonstrated that enzalutamide plus radioligand therapy with 131I-LNTH-1095 significantly improved PSA50 in previously treated patients with metastatic castration-resistant prostate cancer.
Results from the phase 2 ARROW...
04/10/2026
Oncology
News
04/08/2026
Stephanie Holland
Results from the phase 3 VIKTORIA-1 trial demonstrate that gedatolisib-based regimens significantly improved outcomes for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Results from the phase 3 VIKTORIA-1 trial demonstrate that gedatolisib-based regimens significantly improved outcomes for patients with HR-positive, HER2-negative, PIK3CA wild-type advanced breast cancer.
Results from the phase 3...
04/08/2026
Oncology
News
04/06/2026
Stephanie Holland
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial demonstrate that neoadjuvant gemcitabine, oxaliplatin, lenvatinib, and toripalimab significantly improves survival compared with surgery alone in high-risk resectable intrahepatic cholangiocarcinoma.
Results from a phase 2/3 trial...
04/06/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
04/02/2026
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy, which thoracic radiotherapy strategy was associated with improved survival outcomes?
In patients with extensive-stage...
04/02/2026
Oncology
Quiz
04/01/2026
Emily Estrada
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the STELLAR-303 trial demonstrate that zanzalintinib plus atezolizumab does not significantly improve overall survival compared with regorafenib in patients with relapsed/refractory metastatic colorectal cancer...
True or False: Results from the...
04/01/2026
Oncology
Quiz
03/31/2026
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate acceptable tolerability and preliminary signs of clinical activity in patients with advanced solid tumors and recurrent/relapsed high-grade glioma?
Did auceliciclib demonstrate...
03/31/2026
Oncology
Quiz
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology